Litcius/Paper detail

Human single cell RNA-sequencing reveals a targetable CD8+ exhausted T cell population that maintains mouse low-grade glioma growth

Rasha Barakat, Jit Chatterjee, Rui Mu, Xuanhe Qi, Xingxing Gu, Igor Smirnov, Olivia Cobb, Karen Gao, Angelica Barnes, Jonathan Kipnis, David H. Gutmann

2024Nature Communications19 citationsDOIOpen Access PDF

Abstract

In solid cancers, T cells typically function as cytotoxic effectors to limit tumor growth, prompting therapies that capitalize upon this antineoplastic property (immune checkpoint inhibition; ICI). Unfortunately, ICI treatments have been largely ineffective for high-grade brain tumors (gliomas; HGGs). Leveraging several single-cell RNA sequencing datasets, we report greater CD8+ exhausted T cells in human pediatric low-grade gliomas (LGGs) relative to adult and pediatric HGGs. Using several preclinical mouse LGG models (Nf1-OPG mice), we show that these PD1+/TIGIT+ CD8+ exhausted T cells are restricted to the tumor tissue, where they express paracrine factors necessary for OPG growth. Importantly, ICI treatments with α-PD1 and α-TIGIT antibodies attenuate Nf1-OPG tumor proliferation through suppression of two cytokine (Ccl4 and TGFβ)-mediated mechanisms, rather than by T cell-mediated cytotoxicity, as well as suppress monocyte-controlled T cell chemotaxis. Collectively, these findings establish a previously unrecognized function for CD8+ exhausted T cells as specialized regulators of LGG maintenance. With the emergence of immune checkpoint inhibitor therapies for cancer, the authors use single-cell sequencing to assess exhausted T cell content in human glioma samples and leverage these findings in mouse models to define the mechanisms by which exhausted T cells regulate low-grade glioma growth.

Topics & Concepts

TIGITCytotoxic T cellCancer researchGliomaCD8Immune systemT cellBiologyImmunologyImmune checkpointImmunotherapyBiochemistryIn vitroGlioma Diagnosis and TreatmentCancer Immunotherapy and BiomarkersImmune cells in cancer